Citadel Advisors
IRLA

Citadel Advisors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Citadel Advisors’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-780
Closed -$157K – 13997
2025
Q4 		$522K Buy
780
+495
+174% +$249K ﹤0.01% 8928
2025
Q3 		$92.8K Sell
285
-185
-39% -$61.6K ﹤0.01% 11890
2025
Q2 		$155K Buy
470
+268
+133% +$61.3K ﹤0.01% 10925
2025
Q1 		$53.7K Buy
+202
New +$61.7K ﹤0.01% 12244
2024
Q4 		– Sell
-535
Closed -$161K – 15221
2024
Q3 		$83.1K Buy
535
+36
+7% +$5.16K ﹤0.01% 11366
2024
Q2 		$74.9K Buy
499
+367
+278% +$66.3K ﹤0.01% 11287
2024
Q1 		$28K Buy
+132
New +$32.8K ﹤0.01% 12754
2023
Q1 		– Sell
-26
Closed -$5.09K – 15357
2022
Q4 		$3.37K Buy
+26
New +$4.35K ﹤0.01% 14222
2022
Q3 		– Sell
-651
Closed -$248K – 13422
2022
Q2 		$289K Buy
+651
New +$460K ﹤0.01% 9892
2022
Q1 		– Sell
-314
Closed -$427K – 14396
2021
Q4 		$793K Sell
314
-157
-33% -$958K ﹤0.01% 8512
2021
Q3 		$8.63M Buy
+471
New +$7.49M ﹤0.01% 3334
2021
Q2 		– Sell
-164
Closed -$1.38M – 14276
2021
Q1 		$1.18M Sell
164
-243
-60% -$1.75M ﹤0.01% 7688
2020
Q4 		$2.26M Sell
407
-1,110
-73% -$9.83M ﹤0.01% 5102
2020
Q3 		$15.2M Sell
1,517
-211
-12% -$1.92M ﹤0.01% 1822
2020
Q2 		$16M Buy
1,728
+462
+36% +$4.23M 0.01% 1704
2020
Q1 		$11.5M Buy
1,266
+1,234
+3,856% +$12.2M 0.01% 1707
2019
Q4 		$360K Sell
32
-26
-45% -$157K ﹤0.01% 7306
2019
Q3 		$290K Buy
+58
New +$357K ﹤0.01% 7604

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's IRLA Position: Q1 2026 in Review

Citadel Advisors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2026, closing a stake of 780 shares — an estimated $157K sold.

Citadel Advisors first reported a position in IRLA in Q3 2019 and held it in 18 quarters. The position peaked at $16M in Q2 2020. 43 funds tracked by Wall St. Rank hold IRLA as of Q1 2026.

  • Citadel Advisors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 780 IRulya Therapeutics Inc. Common Stock shares in Q1 2026, an estimated $157K.
  • Citadel Advisors first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2019 and held it in 18 quarters.
  • Citadel Advisors's IRulya Therapeutics Inc. Common Stock position peaked at $16M in Q2 2020.
  • 43 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.